Frenette v. Alexion Pharmaceuticals, Inc.

CourtDistrict Court, D. Massachusetts
DecidedSeptember 30, 2024
Docket1:22-cv-11042
StatusUnknown

This text of Frenette v. Alexion Pharmaceuticals, Inc. (Frenette v. Alexion Pharmaceuticals, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Massachusetts primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Frenette v. Alexion Pharmaceuticals, Inc., (D. Mass. 2024).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS

Kathleen Frenette, Leslie Anne Montgomery, * & Suzanne Zuckerman, * * Plaintiffs, * * v. * Civil Action No. 1:22-cv-11042-IT * Alexion Pharmaceuticals Inc., et al., * * Defendants. * *

MEMORANDUM & ORDER

September 30, 2024 TALWANI, D.J. Before the court is Plaintiffs Kathleen Frenette, Leslie Anne Montgomery, and Suzanne Zuckerman’s Motion to Compel Discovery Responses [Doc. No. 73]. For the reasons set forth herein, the Motion is GRANTED IN PART and DENIED IN PART. I. Background Plaintiffs Kathleen Frenette, Leslie Anne Montgomery, and Suzanne Zuckerman assert claims against Defendants Alexion Pharmaceuticals, Inc. (“Alexion”) and Mary Sheila Leese for age discrimination and retaliation. Their claims are related to Alexion’s restructuring, in which employees, including Plaintiffs, had to re-apply for jobs and were subsequently denied positions that they desired. Defendants state that in September 2020, Alexion notified about 85 employees in the Patient Services group, including Plaintiffs, that their roles were being eliminated. Am. Answer [Doc. No. 13] ¶ 35. According to Defendants, Alexion encouraged these employees to apply for positions in the restructured company. Id. at 2 (response to Introduction). Per Defendants’ Chart on Internal Applicants [Doc. No. 73-3], Plaintiffs applied for different roles, including several different levels of Patient Engagement Manager (“PEM”) roles, but these roles went to younger candidates. Defendants claim that for internal candidates, including Plaintiffs, Alexion based hiring decisions on each candidate’s performance during a single interview, without reference to prior performance evaluations or anything in the candidate’s personnel file. Am. Answer [Doc.

No. 13] ¶ 43. Defendants further claim that Plaintiffs were offered level 7 Patient Navigator and Patient Liaison (“PN/PL”) roles at their same base salary, but that Plaintiffs declined these roles. Id. ¶¶ 89, 115; Opposition [Doc. No. 75] at 3 n.1. Plaintiffs maintain that these positions were demotions. Compl. [Doc. No. 1-1] ¶¶ 89, 115. Plaintiffs filed internal complaints of age discrimination on November 5, 2020, after Alexion had extended offers to internal candidates. Am. Answer [Doc. No. 13] ¶¶ 80, 88, 99. Plaintiffs allege that Defendants failed to follow Alexion’s own Equal Employment, Non- Harassment and Non-Discrimination Policy (“EEO Policy”), which states: “The Company hires, assigns, promotes, and retains workers on the basis of their qualifications, relevant work performance and other legitimate factors.” Compl. [Doc. No. 1-1] at ¶ 17.

In January 2021, Kate Dyson, the Compliance Business Partner for the Patient Services Organization, proposed that Alexion create form statements for each candidate who had been selected in October 2020 for the PEM roles. See January 2021 Email re PEM Employment Statement [Doc. No. 73-7] at 4-6. These are the Health Care Professional statements (“HCP statements”) referred to throughout this Memorandum and Order. An HCP statement was allegedly placed into the file of the eleven candidates selected for PEM roles. Defendants acknowledge that these statements were only created and put into the successful candidates’ files several months after the initial hiring process concluded in October 2020. See Opposition [Doc. No. 75] at 8. II. Procedural Background Related to the Discovery Dispute On November 3, 2022, Plaintiffs issued their first set of Requests for Production of Documents [Doc. No. 75-3], including requests 33, 41, 60, 61, 82 and 86 discussed below. Defendants served their response on January 13, 2023, setting forth objections and identifying those documents that Alexion agreed to produce. See Alexion’s Response to Plaintiffs’ Initial

Request for Product of Documents [Doc. No. 74-5]. In February 2023, this court extended the deadline to request production of documents to March 28, 2023, from the previous deadline of November 4, 2022. See Joint Motion to Amend Scheduling Order by Consent [Doc. No. 19] at 2. Plaintiffs did not serve a further request for production of documents during this time. In November 2023, Plaintiffs’ counsel sent a letter advising Defendants’ counsel that Plaintiffs intended to move to compel certain information and seeking a discovery conference to determine if a motion was necessary. See November 3, 2023 Letter from Elizabeth Rodgers to Plaintiffs’ Counsel [Doc. No. 75-5] at 2. In that letter, Plaintiffs made no reference to the specific requests for production at issue, but outlined specific information and documents Plaintiffs

sought, including “the dates of employment, salary, full compensation (base, bonuses, 401k match, RSUs, etc.) through the present for all individuals who have held: (a) all 20 PEM positions, (b) the Senior Manager, Patient Engagement position, and (c) the Associate Director, Patient Services Training and Development position.” Id. On January 12, 2024, Defendants replied to Plaintiffs’ November 2023 request. See Response to Plaintiffs’ November 22, 2023 Correspondence [Doc. No. 74-6] at 1. Defendants refused to provide documents concerning candidates for PEM roles Plaintiffs did not apply for, documents for candidates for roles like the Associate Director and Patient Services Training and Development roles because these roles fell outside of the restructured Patient Services Organization, or any information about any successful candidates’ actual bonuses and RSU distributions but agreed to provide these candidates’ bonus targets and company multipliers for 2021. Id. Plaintiffs and Defendants engaged in further exchanges concerning these requests in

January 2024. Defendants’ counsel memorialized Plaintiffs’ specific requests for continued salary information, actual bonuses, 401k matches, and restricted stock units (RSUs), as well as Plaintiffs’ arguments as to why these materials were relevant, in a January 18, 2024 email. See January 18, 2024 Email from Emily Miller to Elizabeth Rodgers [Doc. No. 74-7] at 3-4. Discovery closed on January 26, 2024—after this court granted a joint motion to extend the end of fact discovery by ten days. See Elec. Order [Doc. No. 58]. On that same day, both parties supplied their final discovery positions. Defendants again stated in their communication that they would not produce continued salary information, actual bonus information, or actual equity information. See January 26, 2024 Email from Lynn A. Kappelman to Elizabeth Rodgers [Doc. No. 74-8] at 2.

In a January 30, 2024 email from Defendants’ counsel to counsel for Plaintiffs, Defendants alleged that counsel for the parties conferred and agreed to supply each other with narrowed requests in writing regarding discovery issues still in dispute, but that Plaintiffs were repeatedly late in supplying these narrowed requests. See January 30, 2024 Email from Emily Miller to Elizabeth Rodgers [Doc. No. 74-10] at 2. Plaintiffs contend that Plaintiffs’ counsel never agreed to narrow their requests. See Motion to Compel [Doc. No. 73] at 10-11. Plaintiffs filed the present Motion to Compel [Doc. No. 73] on February 14, 2024. Both sides seek attorneys’ fees in connection with this motion. See id. at 24; Opposition [Doc. No. 75] at 12. III. Standard of Review Under Federal Rule of Civil Procedure 37(a)(3)(B), a party seeking discovery may move for an order compelling production when another party has failed to produce documents requested under Rule 34. Fed. R. Civ. P. 37(a)(3)(B)(iv). The scope of discovery is governed by Federal Rule of Civil Procedure 26(b)(1), which

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Pierce v. Underwood
487 U.S. 552 (Supreme Court, 1988)
Brady v. Nestor
496 N.E.2d 148 (Massachusetts Supreme Judicial Court, 1986)
Bulwer v. Mount Auburn Hospital
46 N.E.3d 24 (Massachusetts Supreme Judicial Court, 2016)
Rodriguez-Cardi v. MMM Holdings, Inc.
936 F.3d 40 (First Circuit, 2019)
Theidon v. Harvard University
948 F.3d 477 (First Circuit, 2020)
Sheppard v. River Valley Fitness One, L.P.
428 F.3d 1 (First Circuit, 2005)

Cite This Page — Counsel Stack

Bluebook (online)
Frenette v. Alexion Pharmaceuticals, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/frenette-v-alexion-pharmaceuticals-inc-mad-2024.